title: Change and significance of nuclear factor-kappaB in adriamycin induced cardiomyopathy in rats.
abstract: BACKGROUND
  This study aimed at investigating the change and significance of nuclear factor-kappaB (NF-kappaB) in cardiomyopathy induced by adriamycin (ADR) in rats.
  
  
  METHODS
  Sixty male Wistar rats were randomly divided into three groups: control, ADR and ADR + pyrrolidine dithiocarbamate (PDTC) groups. After 30-day experiment, myocardial histopathological observation was performed. Location and distribution of NF-kappaB p50 was examined by immunohistochemical assay. Expression of NF-kappaB p50 protein was examined by immunobolt assay. Electrophoretic Mobility Shift Assay examined activity of NF-kappaB; Myocardium p53 gene expression was examined by RT-PCR analysis.
  
  
  RESULTS
  The myocardial lesions of rats were less pronounced in ADR + PDTC group than in ADR group. Compared with control group, there were many myocardium nucleuses, which expressed NF-kappaB p50 and distribute under epicardium. Expression of NF-kappaB p50 protein in nucleus increased significantly in ADR group. The NF-kappaB binding activity increased significantly in ADR group. Myocardium expressions of p53 mRNA increased in ADR group.
  
  
  CONCLUSIONS
  The NF-kappaB binding activity increased significantly in cardiomyopathy induced by ADR in rats. Moreover, NF-kappaB plays an important role in causing degeneration of myocardial tissue and regulating expression of related-apoptosis genes.
authors.affiliation: Department of Hemopathy, Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China. lihongli0609@yahoo.com.cn
authors.forename: Hong-Li
authors.initials: HL
authors.lastname: Li
authors.forename: Bin
authors.initials: B
authors.lastname: Liu
authors.forename: Ling-wang
authors.initials: LW
authors.lastname: Zhou
authors.forename: Wei-han
authors.initials: WH
authors.lastname: Yu
mesh_terms: D000818:Animals; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000378:metabolism / Q000473:pathology; D004317:Doxorubicin / Q000633:toxicity*; D024202:Electrophoretic Mobility Shift Assay; D016158:Genes, p53; D008297:Male; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism*; D052002:NF-kappa B p50 Subunit; D011498:Protein Precursors; D051381:Rats; D017208:Rats, Wistar
chemical_list: D016328:NF-kappa B; D052002:NF-kappa B p50 Subunit; D011498:Protein Precursors; D004317:Doxorubicin